Alopecia Areata: From Immunopathogenesis to Emerging Therapeutic Approaches

Research cited in this study 66

1. Single-Cell Analysis of Temporal Immune Cell Dynamics in Alopecia Areata Reveals a Causal Role for Clonally Expanded CD8+ T Cells in Disease Cell Reports · 2025
2. Janus Kinase Inhibitors for Alopecia Areata: A Review of Clinical Data Frontiers in Immunology · 2025
3. Local Corticosteroids for Alopecia Areata: A Narrative Review Dermatology and Therapy · 2025
4. Alopecia Areata: Pathogenesis, Diagnosis, And Therapies MedComm · 2025
5. Modulating Immune Responses in Alopecia: Therapeutic Insights and Potential Targets of Antisense Oligonucleotides BMC Immunology · 2025
6. The Relative Efficacy and Safety of Monotherapies for Alopecia Areata: A Network Meta-Analysis Study Journal of Cosmetic Dermatology · 2025
7. IKZF1 and Ikaros Overexpression Results in Alopecia Areata-Like Phenotype in Mice Experimental Dermatology · 2025
8. Patterns of Clinical Response in Patients With Alopecia Areata Treated With Ritlecitinib in the Allegro Clinical Development Programme Journal of the European Academy of Dermatology and Venereology · 2025
9. Long-Term Safety and Efficacy of Ritlecitinib in Adults and Adolescents with Alopecia Areata and at Least 25% Scalp Hair Loss: Results from the ALLEGRO-LT Phase 3, Open-Label Study Journal of the European Academy of Dermatology and Venereology · 2025
10. Mechanism of PPARα Agonist in Alopecia Areata American Journal of Translational Research · 2025
11. Hematological Ratios as an Indicator of Severity in Alopecia Areata: A Retrospective Nationwide Study PLoS ONE · 2024
12. Systematic Review and Indirect Treatment Comparisons of Ritlecitinib Against Baricitinib in Alopecia Areata Journal of the European Academy of Dermatology and Venereology · 2024
13. Mesenchymal Stem Cell Therapy in Alopecia Areata: Visual and Molecular Evidence from a Mouse Model International Journal of Molecular Sciences · 2024
14. Baricitinib Withdrawal and Retreatment in Patients With Severe Alopecia Areata JAMA Dermatology · 2024
15. Alopecia Areata Exhibits Cutaneous And Systemic OX40 Activation Across Atopic Backgrounds Allergy · 2024
16. Efficacy and Safety of Deuruxolitinib, an Oral Selective Janus Kinase Inhibitor, in Adults with Alopecia Areata: Results from the Phase 3 Randomized, Controlled Trial (THRIVE-AA1) Journal of the American Academy of Dermatology · 2024
17. Deciphering the Complex Immunopathogenesis of Alopecia Areata International Journal of Molecular Sciences · 2024
18. Comparative Efficacy and Safety of JAK Inhibitors in the Treatment of Moderate-to-Severe Alopecia Areata: A Systematic Review and Network Meta-Analysis Frontiers in pharmacology · 2024
19. Long-Term Efficacy and Safety of Baricitinib in Patients With Severe Alopecia Areata: 104-Week Results From BRAVE-AA1 and BRAVE-AA2 Journal of the European Academy of Dermatology and Venereology · 2024
20. Dupilumab Therapy for Alopecia Areata: A Case Series and Review of the Literature Journal of Dermatological Treatment · 2024
21. CXCL12 Neutralizing Antibody Promotes Hair Growth in Androgenic Alopecia and Alopecia Areata International Journal of Molecular Sciences · 2024
22. Inhibition of T-Cell Activity in Alopecia Areata: Recent Developments and New Directions Frontiers in immunology · 2023
23. Functional Interrogation of Lymphocyte Subsets in Alopecia Areata Using Single-Cell RNA Sequencing Proceedings of the National Academy of Sciences · 2023
24. SIRT1 Downregulation Provokes Immune-Inflammatory Responses in Hair Follicle Outer Root Sheath Cells and May Contribute to Development of Alopecia Areata Journal of Dermatological Science · 2023
25. The Potential of Regulatory T Cell-Based Therapies for Alopecia Areata Frontiers in Immunology · 2023
26. Alopecia Areata: An Updated Review for 2023 Journal of Cutaneous Medicine and Surgery · 2023
27. Efficacy and Safety of Ritlecitinib in Adults and Adolescents With Alopecia Areata: A Randomised, Double-Blind, Multicentre, Phase 2b–3 Trial The Lancet · 2023
28. Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata Over 52 Weeks in Phase III Trials American Journal of Clinical Dermatology · 2023
29. Diverse Role of OX40 on T Cells as a Therapeutic Target for Skin Diseases Journal of Investigative Dermatology · 2023
30. Involvement of ILC1-Like Innate Lymphocytes in Human Autoimmunity: Lessons from Alopecia Areata eLife · 2023
31. Induction of T Cell Exhaustion by JAK1/3 Inhibition in the Treatment of Alopecia Areata Frontiers in immunology · 2022
32. An Overview of JAK/STAT Pathways and JAK Inhibition in Alopecia Areata Frontiers in immunology · 2022
33. Selective Expansion of Tregs Using the IL-2 Cytokine Antibody Complex Does Not Reverse Established Alopecia Areata in C3H/HeJ Mice Frontiers in immunology · 2022
34. Autoantigen Discovery in the Hair Loss Disorder, Alopecia Areata: Implications of Post-Translational Modifications Frontiers in immunology · 2022
35. The Role of Serum Th1, Th2, and Th17 Cytokines in Patients with Alopecia Areata: Clinical Implications Cells · 2021
36. Ritlecitinib And Brepocitinib Demonstrate Significant Improvement In Scalp Alopecia Areata Biomarkers ˆThe ‰journal of allergy and clinical immunology/Journal of allergy and clinical immunology/˜The œjournal of allergy and clinical immunology · 2021
37. Alopecia Areata: An Update on Etiopathogenesis, Diagnosis, and Management Clinical Reviews in Allergy & Immunology · 2021
38. Hair Growth Promotion by Necrostatin-1s Scientific Reports · 2020
39. Pro-Inflammatory Vδ1+ T-Cells Infiltrates Are Present In And Around The Hair Bulbs Of Non-Lesional And Lesional Alopecia Areata Hair Follicles Journal of Dermatological Science · 2020
40. Low-Dose IL-2 for Treating Moderate to Severe Alopecia Areata: A 52-Week Multicenter Prospective Placebo-Controlled Study Assessing Its Impact on T Regulatory Cell and NK Cell Populations ˜The œjournal of investigative dermatology/Journal of investigative dermatology · 2020
41. Alopecia Areata Patients Show Deficiency of FOXP3+CD39+ T Regulatory Cells and Clonotypic Restriction of Treg TCRβ-Chain, Highlighting the Immunopathological Aspect of the Disease PloS one · 2019
42. Alopecia Areata Is Characterized by Dysregulation in Systemic Type 17 and Type 2 Cytokines, Which May Contribute to Disease-Associated Psychological Morbidity British journal of dermatology/British journal of dermatology, Supplement · 2019
43. High-Throughput T Cell Receptor Sequencing Identifies Clonally Expanded CD8+ T Cell Populations in Alopecia Areata JCI insight · 2018
44. An Integrated Model of Alopecia Areata Biomarkers Highlights Both TH1 and TH2 Upregulation Journal of Allergy and Clinical Immunology · 2018
45. iNKT Cells Ameliorate Human Autoimmunity: Lessons from Alopecia Areata Journal of autoimmunity · 2018
46. Efficacy of Diphenylcyclopropenone in Alopecia Areata: A Comparison of Two Treatment Regimens Postępy Dermatologii i Alergologii · 2018
47. Pharmacologic Inhibition of JAK-STAT Signaling Promotes Hair Growth Science Advances · 2015
48. Alopecia Areata Profiling Shows TH1, TH2, and IL-23 Cytokine Activation Without Parallel TH17/TH22 Skewing ˆThe ‰journal of allergy and clinical immunology/Journal of allergy and clinical immunology/˜The œjournal of allergy and clinical immunology · 2015
49. Imbalance of T-Helper 17 and Regulatory T Cells in Patients with Alopecia Areata The Journal of Dermatology · 2015
50. Hair Regrowth in Alopecia Areata Patients Following Stem Cell Educator Therapy BMC medicine · 2015
51. The Genetics Of Alopecia Areata: New Approaches, New Findings, New Treatments Journal of Dermatological Science · 2015
52. Plasmacytoid Dendritic Cells in Alopecia Areata: Missing Link? Journal of the European Academy of Dermatology and Venereology · 2014
53. Diagnostic Usefulness of a Peribulbar Eosinophilic Infiltrate in Alopecia Areata JAMA Dermatology · 2014
54. Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition Nature medicine · 2014
55. Tolerance Induction by Hair-Specific Keratins in Murine Alopecia Areata Journal of Leukocyte Biology · 2013
56. Histologic Features of Alopecia Areata Other Than Peribulbar Lymphocytic Infiltrates 2011
57. Trichohyalin Is a Potential Major Autoantigen in Human Alopecia Areata Journal of Proteome Research · 2010
58. Genome-Wide Association Study in Alopecia Areata Implicates Both Innate and Adaptive Immunity Nature · 2010
59. Alopecia Areata as Another Immune-Mediated Disease Developed in Patients Treated with Tumor Necrosis Factor-Alpha Blocker Agents Journal of the European Academy of Dermatology and Venereology · 2010
60. Experimental Evaluation of Ebastine, a Second-Generation Antihistamine, as a Supportive Medication for Alopecia Areata Journal of Dermatological Science · 2010
61. Maintenance of Hair Follicle Immune Privilege Is Linked to Prevention of NK Cell Attack Journal of Investigative Dermatology · 2007
62. Recurrence of Alopecia Areata in a Patient Receiving Etanercept Injections Archives of Dermatology · 2005
63. Characterization of Hair Follicle Antigens Targeted by the Anti-Hair Follicle Immune Response Journal of Investigative Dermatology Symposium Proceedings · 2003
64. Expression of Peroxisome Proliferator Activated Receptors (PPARs) in Human Hair Follicles and PPARα Involvement in Hair Growth Acta dermato-venereologica · 2000
65. Eosinophils in Fibrous Tracts and Near Hair Bulbs: A Helpful Diagnostic Feature of Alopecia Areata Journal of the American Academy of Dermatology · 2000
66. Eosinophils in Fibrous Tracts and Near Hair Bulbs: A Helpful Diagnostic Feature of Alopecia Areata Journal of The American Academy of Dermatology · 1997